| Title |
Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, July 2017
|
| DOI | 10.2147/ndt.s130444 |
| Pubmed ID | |
| Authors |
Michael Huss, Praveen Duhan, Preetam Gandhi, Chien-Wei Chen, Carsten Spannhuth, Vinod Kumar |
| Abstract |
Attention-deficit/hyperactivity disorder (ADHD) is a chronic psychiatric disorder characterized by hyperactivity and/or inattention and is often associated with a substantial impact on psychosocial functioning. Methylphenidate (MPH), a central nervous system stimulant, is commonly used for pharmacological treatment of adults and children with ADHD. Current practice guidelines recommend optimizing MPH dosage to individual patient needs; however, the clinical benefits of individual dose optimization compared with fixed-dose regimens remain unclear. Here we review the available literature on MPH dose optimization from clinical trials and real-world experience on ADHD management. In addition, we report safety and efficacy data from the largest MPH modified-release long-acting Phase III clinical trial conducted to examine benefits of dose optimization in adults with ADHD. Overall, MPH is an effective ADHD treatment with a good safety profile; data suggest that dose optimization may enhance the safety and efficacy of treatment. Further research is required to establish the extent to which short-term clinical benefits of MPH dose optimization translate into improved long-term outcomes for patients with ADHD. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 174 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 174 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 33 | 19% |
| Student > Master | 26 | 15% |
| Researcher | 13 | 7% |
| Other | 9 | 5% |
| Student > Postgraduate | 6 | 3% |
| Other | 24 | 14% |
| Unknown | 63 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 17% |
| Psychology | 15 | 9% |
| Neuroscience | 11 | 6% |
| Nursing and Health Professions | 10 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 6% |
| Other | 29 | 17% |
| Unknown | 70 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2023.
All research outputs
#1,812,482
of 25,382,440 outputs
Outputs from Neuropsychiatric Disease and Treatment
#226
of 3,131 outputs
Outputs of similar age
#34,568
of 326,871 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#7
of 92 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,871 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.